Sandra Carson - 26 Aug 2024 Form 4 Insider Report for AGILE THERAPEUTICS INC

Role
Director
Signature
/s/ Geoffrey P. Gilmore, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
26 Aug 2024
Net transactions value
-$1,479
Form type
4
Filing time
26 Aug 2024, 17:34:33 UTC
Previous filing
09 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGRX Common Stock Disposed to Issuer $1,479 -973 -100% $1.52 0 26 Aug 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Sandra Carson is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 973 shares of Common Stock were converted into the right to receive into the right to receive a cash payment of $1.52 (the "Merger Consideration") per share of Common Stock, for an aggregate of $1,479, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person